Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Proforma Information (Details)

v3.23.2
Business combinations - Proforma Information (Details) - USD ($)
3 Months Ended 5 Months Ended 6 Months Ended
Jun. 01, 2023
Jun. 30, 2023
Jun. 30, 2022
May 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Merger with TCR2 Therapeutics Inc.            
Gain on bargain purchase   $ 22,155,000     $ 22,155,000  
Share-based compensation expense   $ 3,837,000 $ 5,045,000   5,513,000 $ 10,631,000
TCR2 Therapeutics            
Merger with TCR2 Therapeutics Inc.            
Revenue         52,731 9,113
Net loss         (86,202) (143,556)
Acquisition-related costs incurred by TCR2         7,700,000  
Gain on bargain purchase $ 22,155,000       22,200,000  
Acquisition-related costs         $ 7,165,000  
Share-based compensation expense       $ 1,000,000.0   $ 6,000,000.0